Objective: Determine whether hot flashes, depressed mood, sleep, cognitive and sexual symptoms correlate with urinary follicle-stimulating hormone (FSH), estrone (E 1 G) and testosterone (T) and with each other during the menopausal transition and early postmenopause (PM).
Introduction
The relationship among reproductive endocrine levels and severity of symptoms women experience during the transition to menopause and early postmenopause (PM) has captured the interest of clinicians, investigators and women themselves. Women attribute many types of symptoms to the menopausal transition: hot flashes, sweats, sleep disruption, mood changes and changes in sexual desire 1 . In the post Women's Health Initiative era, clinicians and researchers search for new symptom management approaches for women with severe symptoms 2, 3 , and women, themselves, demonstrate increasing interest in complementary and alternative medicine as therapies 4 .
Hot flashes and sweats increase in prevalence as women approach the final menstrual period 5 . In longitudinal studies of midlife women, vasomotor symptoms were associated with leutenizing hormone (LH) pulses 6, 7 , low estradiol 8, 9, 10 , low inhibin levels 8 , and high levels of follicle-stimulating hormone (FSH) [8] [9] [10] [11] . Both serum-hormone binding globulin (SHBG) and free estradiol levels (FEI) were also associated with a lower prevalence of hot flashes 10 . In one study increased androgen levels were associated with a decreased frequency of postmenopausal vasomotor symptoms 12 . In acute studies of hot flashes where laboratory stimuli were used to induce the symptom, elevations in LH, adrenocorticotropic hormone (ACTH), gonadotropic hormone (GH), and cortisol all were closely associated in time with the experience of the hot flash, but no changes were reported in estradiol and FSH levels 13, 14 .
During the menopausal transition women also report perceptions of disrupted sleep. They commonly attribute these disruptions to hormonal changes, and hot flashes, which they believe cause awakening 1 . In contrast to women's explanatory models for sleep symptoms, evidence from recent studies showed that women awaken, then have a hot flash 15 . Sleep symptoms have been associated with increased FSH during the late reproductive stage and to increased levels of pregnanediol and FSH in the perimenopause 16 . In another study, lower 5 estradiol levels were associated with sleep symptoms among women who were still cycling regularly 17 .
Recently reported longitudinal study results indicate an association of higher FSH and LH levels and increased variability of estradiol, FSH, and LH (within women) with depressed mood symptoms 18, 19 , as well as lower levels of estradiol 19, 20 and dehydroepiandrosterone (DHEAS) 21, 22 . Whether an increase in the incidence of depressed mood occurs as women traverse the menopausal transition and whether the early or late menopausal transition stages are times of vulnerability to depression remain to be determined 19, [23] [24] [25] .
Although women often notice cognitive symptoms, which they describe as forgetfulness or difficulty concentrating, few women rate these symptoms as serious 26 . They do attribute these symptoms to changing hormones as well as general aging and life stress 27 . To date cognitive symptoms have not been studied with a longitudinal design, although the Study of Women Across the Nation (SWAN) has reported stage-specific prevalence of forgetfulness ranging from 31 percent during the late reproductive stage to 42 percent in the PM 28 . The single longitudinal assessment of cognitive functions indicated that the changes were related to aging 29 . Nonetheless, there has been widespread interest in the use of hormone therapy to prevent cognitive decline and little evidence of efficacy 30, 31 To date there are a few reports from longitudinal studies of the relationship between hormone levels and changes in sexual desire 32, 34 . Low estradiol levels have been associated with dyspareunia 34 , and lower sexual functioning scores in the Melbourne Midlife Women's Health Study were associated with higher FSH levels and lower estradiol levels 33 . Although there was no relationship with testosterone in the Melbourne study, participants in the Penn
Ovarian Aging study who experienced fluctuation in testosterone levels experienced more sexual functioning symptoms 35 .
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The results of previous work suggest that the hypothalamic-pituitary-ovarian axis hormonal changes occurring during the menopausal transition may be linked to several groups of symptoms, including hot flashes, sleep disturbances, depressed mood, and decreased sexual functioning 36 . Many reports of the relationships between symptoms and endocrine levels were based on cross-sectional analyses of data from women in different phases of the menopausal transition. Moreover, in many of the large longitudinal studies, the estimates of endocrine levels are based on an annual blood draw in which serum levels of hormones with a pulsatile release pattern form the bases for the estimate. The Seattle Midlife Women's Health Study (SMWHS) has focused on the transition to menopause for a smaller number of women than the large studies but has collected urinary hormone levels based on a first morning sample several times each year of the study, up to nine years 37 . The ability to study these phenomena with frequent, repeated measures over several years as a part of a prospective, longitudinal study of the menopausal transition provides the opportunity to conduct intensive within woman analyses of the relationships among symptoms and endocrine change over the menopausal transition.
The purposes of this study were to: 1) Determine the relationship between urinary endocrine levels (E 1 G, FSH, and T) and the severity of symptoms (hot flashes, sleep disruption, depressed mood, sexual and cognitive)
women experience during the menopausal transition.
2) Determine the relationships among symptoms experienced during the menopausal transition, specifically, hot flashes, early awakening, waking during the night, depressed mood, forgetfulness, difficulty concentrating, decreased sexual desire and vaginal dryness.
Methods
Design and Sample. The data for these analyses are part of the SMWHS, a larger longitudinal study. Urinary Assays. Urinary assays were performed in our laboratories using a first-voided morning urine specimen provided on day 6 of the menstrual cycle, if menstrual periods were identifiable. For women with no bleeding or spotting or extremely erratic flow, a consistent date was used. Women abstained from smoking, caffeine use, and exercise before the urine collection. Urine samples were preserved with sodium ethylenediaminetetraacectic acid and sodium metabisulfite and frozen at -70°C.
All specimens, standards and controls were tested in duplicate and those with a coefficient of variance above 15% were repeated. A BioRad Quantitative Urine control and a pooled inhouse urine control were included in all assays, and a member of the standard curve was repeated after every ten unknowns to monitor assay performance. Multiple samples from each subject were included in the same assays during each year. In general, all samples from a calendar year were assayed during the next calendar year.
Urinary creatinine. All endocrine concentrations were corrected for variations in urine concentration by expressing the hormone level as a ratio to the concentration in the same urine specimen. Urine specimens were assayed for creatinine using the method of Jaffe 46 .
The inter-assay variation (run to run) was 6.7% and the intra-assay variation was 3.1% (n = 405).
Urinary estrone glucuronide (E 1 G). E 1 G was used for measuring estrogen because it is
stable, can be reliably measured without special preparation, and is highly correlated with serum estradiol levels [40] [41] [42] [43] [44] . Urinary E 1 G was measured by a competitive enzyme immunoassay (EIA) that cross-reacts 100% with E 1 G, 83% with estradiol glucuronide and less than 10% with free estrone, estrone sulfate, estriol glucuronide, estradiol and estriol 42 .
Urinary E 1 G concentrations estimated from this EIA were highly correlated with serum 9 estradiol (Pearson's r=0.95; based on 30 averaged cycles) 42 . The lower limit of detection for the assay was 3.1 nmol/L. Average recovery from a urine matrix of low, medium and high E 1 G standard doses was 101% 42 . Intra-and inter-assay coefficients of variation (CV) were 2.1% and 9.6%, respectively, for an external (BioRad) urine control (mean concentration 2.1ng/mL); and 2.8% and 14.5%, respectively, for an internal urine control (mean concentration 1.59 ng/mL) (determined using the method of Rodbard 45 from 20 randomly selected plates). There was no evidence of trending in the urine control specimens across the study: the inter-assay CV from 255 microtiter plates was 10.1% for the internal control and 10.8% for the external control. E 1 G concentration was estimated from absorbance (Dynatech MR7000 Plate reader, test wavelength 405 nm; reference wavelength 570 nm) using a four parameter logistic in Biolinx 1.0 Software (Dynex Laboratories). E 1 G concentrations were corrected for slight assay non-parallelism 42 and standardized to a 1:5 dilution for all specimens.
Urinary FSH. FSH was assayed using Diagnostic Products Corporation (DPC) Double
Antibody FSH Kit. This radioimmunoassay (RIA) was designed for the quantitative measurement of FSH in serum and urine. An extraction of urinary FSH was done to achieve the necessary sample concentration and to insure matrix compatibility between the calibrator and the unknowns. Recoveries for extraction were in the order of 95%. The DPC protocol for extracting the FSH from the urine specimen used sodium acetate and spectrophotometric grade acetone. Following an overnight freeze, the FSH was precipitated by centrifugation and the solvent was removed by aspiration in a fume hood. The FSH levels were determined by measuring counts per minute using a Cobra Series AutoGamma Counting System. Unknown FSH levels were inversely related to tube counts and interpolated from a logit-log representation derived from calibrators ranging from 2 to 100 mIU/ml. Standards ranging from 5 to 40 mIU/mL were used throughout the study to calculate variance 47 . FSH levels used in the analyses were reported as mIU/mg creatinine.
The reporting range for urine FSH was 2.0 to100 mIU/mL, the minimum detectable concentration was 1.6 mIU. The inter-assay variation (run to run) was 7.1% and the intraassay variation (within run) was 3.7% (N=205).
Urinary testosterone (T). Testosterone levels were assayed using the DPC Total
Testosterone Kit, a solid-phase RIA using a testosterone-specific antibody immobilized to the wall of a polypropylene tube [48] [49] [50] . A hydrolysis step preceded the assay and was accomplished by addition of concentrated hydrochloric acid to the urine specimens. The acidified samples were then boiled for 15 minutes to remove any interfering substances from the urine. The hydrolyzed urine was diluted into a testosterone-free zero matrix, incubated in the tubes and then evaluated by RIA. Labeled 125 I-testosterone was added to all samples and competed with the T present in the sample for binding sites on the tube walls during a threehour incubation at 37C. The unbound testosterone was decanted and the remaining 125 Itestosterone determined by measuring counts per minute using a Cobra Series Auto-Gamma
Counting System as with FSH. The calibration curve was prepared using standards ranging from zero to 400ng/dl. The inter-assay variation (run to run) was 12.38% (N=791) and the intra-assay variation (within run) was 8.75%. Standards ranging from 25 to 400ng/dl were used throughout the study to calculate recovery. The average recovery was 92.7% and ranged from 86.1 to 106%. T levels used in the analysis were reported as ng testosterone per mg creatinine.
Symptoms. Symptoms were measured with the 3-day diary. Women rated each symptom on a scale from 0 (not present) to 4 (extreme) for the past 24 hours. Ratings were averaged over 3 days spanning the date of urine sample collection. Hot flashes, depressed mood, cognitive symptoms of forgetfulness and difficulty concentrating, sleep symptoms of early morning awakening and awakening during the night, and decreased sexual desire and vaginal dryness were analyzed separately.
Analyses
Intra-individual analyses of repeated measures of symptoms and endocrine values were the primary foci of these analyses. To test the null hypothesis that there was no association between a particular symptom and a particular assay (or another symptom) we used a nonparametric procedure consisting of Spearman's rho combined with a sign test (the latter is the same as a binomial test in which both outcomes are regarded as equally likely). For a given woman, symptom and assay data obtained within 3 days of one another were paired.
Spearman's rho was computed for the paired data for each woman. This measure of association was used rather than the more familiar Pearson product moment correlation coefficient because both the assay and its log transform had heavy-tailed distributions, which can cause the sample correlation coefficient to be inordinately influenced by a small number of data points. Under the null hypothesis, any deviation from zero in computed rhos was assumed to be equally likely to be positive or negative. The sign (binomial) test was calculated to determine whether the ratio of positive Spearman's rhos to the total number of rhos was significantly greater or less than what was expected by chance, i.e., 1/2. There were no instances in which the computed rho was exactly zero.
Results
Participants: Data were obtained from a total of 41 women who entered the study between 1990 and 1992 and provided menstrual calendar, diary symptom and assay data on at least ten occasions spanning their middle transition stage to at least one year PM. None of the women was taking exogenous estrogens, progestins, selective estrogen receptor modulators (SERMS) or corticosteroids. The 41 women meeting study inclusion criteria compared to those not meeting criteria (n=201) were similar with respect to age, years of education, BMI, income level, employment status, race/ethnicity, and partnered/married status. As seen in Table 1 there were no significant differences between these two groups of women.
Correlations between Hormones and Symptoms: Table 2 shows the relationship between hormone levels and symptom severity and provides the average Spearman's rho and its standard deviation, the ratio of positive rhos to the total number of rhos, and the associated confidence intervals and p value for the sign test for all women with data for these analyses. In summary, Spearman's rhos between endocrine levels and symptom severity ratings for women spanning the middle stage of the menopausal transition to PM revealed that:
• Severity of hot flashes was positively associated with FSH and negatively with E 1 G.
• Vaginal dryness was positively associated with FSH; negatively associated with T.
• Severity of early morning awakening, awakening during the night and depressed mood were not associated with E 1 G, FSH or T.
• Decreased sexual desire was associated negatively with E 1 G levels.
• Forgetfulness was positively associated with FSH; difficulty concentrating was negatively associated with T.
In addition, rhos among the symptoms revealed that all trended in the positive direction:
• Severity of hot flashes was associated with early morning awakening, awakening during the night, and forgetfulness.
• Early awakening and awakening during the night were associated with depressed mood, as well as hot flashes; awakening during the night was also associated with decreased sexual desire and vaginal dryness.
• Depressed mood was associated with both symptoms of sleep disruption as well as difficulty concentrating and decreased sexual desire, but not hot flashes or vaginal dryness.
• Forgetfulness was associated with hot flashes and difficulty concentrating, whereas difficulty concentrating was associated with depressed mood and early awakening.
• Decreased sexual desire was associated with awakening during the night, depressed mood and vaginal dryness.
• Vaginal dryness was associated with decreased sexual desire and awakening during the night.
Discussion
Taken together, these findings suggest that the symptoms many women experience during the menopausal transition are uniquely related to different endocrine levels (FSH, E 1 G, and T).
Indeed, in the women studied here, early morning awakening, awakening in the night, and depressed mood were not related significantly to any of the endocrine values studied. In addition, hot flashes were related to only the sleep symptoms and forgetfulness, but not to depressed mood as has been suggested in other studies 18, 19 .
The relationship of FSH to vasomotor symptoms has been seen in studies in addition to the SMWHS. Most recently the SWAN study revealed findings of a positive relationship between FSH and hot flashes. Hypothesized mechanisms for vasomotor symptoms include neuroendocrine (alpha adrenergic and central noradrenergic) mechanisms 6, 51 . In addition, E 1 G was associated with hot flashes in the SMWHS cohort, similar to findings in the SWAN cohort. Randolph and associates found that estradiol had less effect than FSH on hot flashes,
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suggesting that nonsteroidal feedback systems are more relevant to the severity of hot flashes than estradiol and that neuroendocrine/gonadal peptide therapies for hot flashes may warrant future attention of investigators 52 . In the Seattle study, severity of hot flashes was not significantly related to T, although in a European cohort serum testosterone was related to a decrease in hot flashes among women during the PM 12,53 .
We did not find that women with higher levels of urinary E 1 G had less severe sleep disruption, inconsistent with results of Hollander's report from the Penn Ovarian Aging
Study which revealed that women who were still having regular cycles but who had lower estradiol levels were more likely to have sleep disruption 17 . In contrast, Kravitz found sleep problems associated with higher FSH levels in women during the late reproductive stage and with higher pregnanediol and higher FSH levels in women during perimenopause 16 .
The lack of a relationship between severity of depressed mood and levels of endocrine hormones is unique in our data. Elevated FSH and lower estradiol levels were associated with depressed mood as measured by the Center for Epidemiologic Studies, Depression (CESD) Scale and with a clinical interview in the Penn Ovarian Aging Study, but the study is limited by the small number of women in the late transition phase and PM 18, 19 . As a result, it is difficult to determine whether these relationships will be sustained among their cohort as more women progress through the menopausal transition to the PM.
As E 1 G becomes the predominant estrogen for women traversing the menopausal transition our finding of a consistent negative relationship between E 1 G and decreased sexual desire would seem to corroborate Dennerstein et al's 32, 33 findings associating decreased estrogens, not androgen, with changes in sexual functioning. While T was not significantly associated with sexual desire in our study, it was negatively associated with vaginal dryness and FSH was positively associated with vaginal dryness. It is possible that T effects on vaginal dryness observed in our study may indicate that androgens, which are metabolic precursors to estrogen synthesis, may be influential as women traverse the menopausal transition.
Testosterone has been reported to both remain stable and to fluctuate throughout the menopausal transition and early PM 36, 53 Awakening in response to the temperature change could activate the CNS with a resultant increase in core body temperature that could be perceived as a hot flash.
We found that hot flashes were related to both early morning awakening and awakening during the night as well as forgetfulness, but hot flashes and depressed mood were not directly related. Instead, sleep symptoms were related to depressed mood, as was forgetfulness, difficulty concentrating, and decreased sexual desire 
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